Orbit Genomics today announced that it is the grand prize winner of the Startup Prize Focus on Health 2025 in the Non-FDA track, a nationally recognized competition spotlighting transformative innovation in healthcare and life sciences.
Selected from a record-breaking pool of 75 startups across 23 states, Orbit Genomics was recognized for its patented OrbiSeq™ platform, an AI-powered approach to advance precision medicine through earlier detection and prevention of complex diseases, beginning with lung cancer.
This award highlights the impact and potential of Orbit Genomics’ patented OrbiSeq™ platform, an AI-powered approach designed to revolutionize diagnosis, treatment, and prevention of complex diseases including cancer, cardiovascular disease, and neurological disorders.
As a grand prize winner, Orbit Genomics receives a $10,000 cash prize, as well as mentorship and introductions to potential investors and partners, extending the company’s access to a national network of healthcare leaders, investors, mentors, and strategic partners. This network is designed to accelerate emerging companies with scalable solutions to some of today’s most urgent health challenges.
“Winning the Startup Prize Focus on Health is an incredible honor for Orbit Genomics,” said Dede Willis, CEO of Orbit Genomics. “Beyond the recognition, this experience has given us invaluable exposure to investors, mentors, and collaborators who share our mission of transforming disease prevention and diagnosis through precision health.”
For Orbit Genomics, this recognition is a milestone on the path to advancing proactive, personalized healthcare and delivering solutions that can change the trajectory of disease at scale.